scholarly journals Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Jie Ma ◽  
Huaxi Xu ◽  
Shengjun Wang
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Cancer Death ◽  
Combined Treatments ◽  
Therapeutic Targeting ◽  
Multiple Factors ◽  
Lung Cancer Therapy

Lung cancer is the leading cause of cancer death worldwide due to its late diagnosis and poor outcome. Immunotherapy is becoming more and more encouraging and promising in lung cancer therapy. Myeloid-derived suppressor cells (MDSCs) are the main tumor suppressor factors, and the treatment strategy of targeting MDSCs is gradually emerging. In this review, we summarize what is currently known about the role of MDSCs in lung cancer. In view of the emerging importance of MDSCs in lung cancer, the treatment of targeting MDSCs will be useful to the control of the development and progression of lung cancer. However, the occurrence, metastasis, and survival of cancer is the result of multiple factors and multiple mechanisms, so combined treatments using different strategies will become the major therapy method for lung cancer in the future.

The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice

2021 ◽  
Vol 10 (4) ◽  
pp. 75
Author(s):  
A.A. Izmailov ◽  
A.F. Nasretdinov ◽  
A.V. Sultanbaev ◽  
D.D. Sakaeva ◽  
K.V. Menshikov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Practice ◽  
Cancer Therapy ◽  
Second Generation ◽  
Egfr Inhibitors ◽  
Lung Cancer Therapy

Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor

2007 ◽  
Vol 3 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Giulio Rossi ◽  
Alessandro Marchioni ◽  
Giuliana Sartori ◽  
Lucia Longo ◽  
Silvia Piccinini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Therapy

Versatile role of curcumin and its derivatives in lung cancer therapy

2020 ◽  
Vol 235 (12) ◽  
pp. 9241-9268 ◽  
Author(s):  
Milad Ashrafizadeh ◽  
Masoud Najafi ◽  
Pooyan Makvandi ◽  
Ali Zarrabi ◽  
Tahereh Farkhondeh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Lung Cancer Therapy

The Role of Pemetrexed (Alimta®, LY231514) in Lung Cancer Therapy

2003 ◽  
Vol 5 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Julian R. Molina ◽  
Alex A. Adjei
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Lung Cancer Therapy

scholarly journals Prognostic Role of Monocytic Myeloid-Derived Suppressor Cells in Advanced Non-Small-Cell Lung Cancer: Relation to Different Hematologic Indices

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Asmaa M. Zahran ◽  
Helal F. Hetta ◽  
Zeinab Albadry M. Zahran ◽  
Alaa Rashad ◽  
Amal Rayan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Suppressor Cells ◽  
Small Cell ◽  
Myeloid Derived Suppressor Cells ◽  
Small Cell Lung ◽  
Prognostic Role

Background and Aim. Myeloid-derived suppressor cells (MDSCs) contribute to the process of malignant transformation and tumor progression through immuno- and nonimmunosuppressive mechanisms. The current study is aimed at providing the predictive and prognostic role of Mo-MDSCs in advanced non-small-cell lung cancer (NSCLC) in relation to different hematologic indices. Methods. We recruited 40 cases of advanced NSCLC, stages III and IV, aged > 18 – < 70 years old, and eligible to receive chemotherapy with or without radiotherapy, along with 20 healthy controls of comparable age and sex; after diagnosis and staging of patients, blood samples were collected for flow cytometric detection of Mo-MDSCs. Results. Significant accumulation of Mo-MDSCs in patients compared to their controls ( p < 0.0001 ). Furthermore, these cells accumulated significantly in stage IV compared to stage III ( p = 0.006 ) and correlated negatively with overall survival ( r = − 0.471 , p = 0.002 ), lymphocyte to monocyte ratio ( r = − 0.446 , p = 0.004 ), and mean platelet volume to platelet count ratio (MPV/PC) ( r = − 0.464 , p = 0.003 ), patients with Mo ‐ MDSCs < 13 % had significantly better survival than those with Mo ‐ MDSCs ≥ 13 % ( p = 0.041 ). Conclusion. Mo-MDSCs represent one of the key mechanisms in the immunosuppressive tumor microenvironment (TME) to play major roles not only in the carcinogenesis of lung cancer but also in disease progression and prognosis and, in addition, predict the efficacy of immune checkpoint inhibitors; our results provided some support to target Mo-MDSCs and needed to be augmented by further studies.

Sign in / Sign up

Export Citation Format

Share Document